Posters & Publications
Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 ± pertuzumab in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan
Presented at: 2023 San Antonio Breast Cancer Symposium
Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001+/- nivolumab in patients with advanced HER2+ colorectal (CRC), endometrial, and gastroesophageal (GE) and breast (BC) cancers
Presented at: 2023 Society for Immunotherapy of Cancer (SITC)
A phase 1/2 study of BDC-3042, a novel Dectin-2 agonistic antibody, in patients with advanced cancers
Presented at: 2023 Society for Immunotherapy of Cancer (SITC)
The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab
Presented at: 2023 Society for Immunotherapy of Cancer (SITC)
Preclinical Characterization of a Novel Claudin 18.2 Targeting-ISAC with Robust Potency and Acceptable Safety Profile
Presented at: 2023 Society for Immunotherapy of Cancer (SITC)
A Phase 1/2 Study of a First-in-Human Immune-Stimulating Antibody Conjugate (ISAC) in Patients with Advanced HER2-Expressing Solid Tumors (NCT04278144)
Presented at: 2023 European Society for Medical Oncology (ESMO) Congress
A Phase 1/2 Study of a First-in-Human Immune-Stimulating Antibody Conjugate (ISAC) BDC-1001 in Patients with Advanced HER2-Expressing Solid Tumors (NCT04278144)
Presented at: 2023 American Society of Clinical Oncology (ASCO)
Targeting Tumor-Associated Macrophages To Enhance Anti-Tumor Immunity With the Dectin-2 Agonistic Antibody BDC-3042
Presented at: 2023 American Association for Cancer Research (AACR)
BDC-3042: A Dectin-2 Agonistic Antibody for Tumor-Associated Macrophage-Directed Immunotherapy
Presented at: 2022 Society for Immunotherapy of Cancer (SITC)
Characterization of Tumor Antigen Expression and Myeloid Immune Profiles to Inform the Development of Immune Stimulating Antibody Conjugates (ISACs)
Presented at: 2022 American Society of Clinical Oncology (ASCO)
Dectin-2 Agonist Antibodies Reprogram Tumor-Associated Macrophages To Drive Anti-Tumor Immunity
Presented at: 2022 American Association for Cancer Research (AACR)
PD-L1-Targeted ISAC Combines Myeloid Cell Activation, Immune-Checkpoint Inhibition and ADCP To Improve Anti-Tumor Efficacy Over Anti-PD-L1 Antibodies in Preclinical Models
Presented at: 2022 American Association for Cancer Research (AACR)
Preliminary Results From a Phase 1/2 Study of BDC-1001, a Novel HER2 Targeting TLR7/8 Immune-Stimulating Antibody Conjugate (ISAC), in Patients (Pts) With Advanced HER2-Expressing Solid Tumors
Presented at: 2021 ESMO Immuno-Oncology Congress
Dectin-2, a Novel Target for Tumor Macrophage Reprogramming in Cancer Immunotherapy
Presented at: 2021 Society for Immunotherapy of Cancer (SITC)
PD-L1-targeted ISAC Combines Myeloid Cell Activation, Immune Checkpoint Inhibition and ADCP to Improve Anti-tumor Efficacy Over Anti-PD-L1 Antibodies in Preclinical Models
Presented at: 2021 Society for Immunotherapy of Cancer (SITC)
Preliminary results from a Phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors
Presented at: 2021 American Society of Clinical Oncology (ASCO)
Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with anti-PD1 antibody in patients (pts) with HER-2 expressing advanced solid tumors
Presented at: 2021 American Association for Cancer Research (AACR)
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity
Ackerman SE, et al., Nature Cancer (2020)
Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
Presented at: 2020 San Antonio Breast Cancer Symposium
Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
Presented at: 2020 Society for Immunotherapy of Cancer (SITC)
Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcγR- and TLR- signaling and enables safe systemic administration
Presented at: 2020 Society for Immunotherapy of Cancer (SITC)
Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models
Presented at: 2020 Society for Immunotherapy of Cancer (SITC)
HER2-targeting TLR 7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR-dependent manner
Presented at: 2019 Society for Immunotherapy of Cancer (SITC)
TLR7/8 immune stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity
Presented at: 2019 American Association for Cancer Research (AACR)
Systemic immunity is required for effective cancer immunotherapy
Spitzer MH et al., Cell (2017)
Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity
Carmi Y, et al., Nature (2015)